Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 23/07/20261 min de lecture
Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
Traduction automatique locale · Langue originale de la source
Résumé
The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Modala Bio, Inc. (Modala), headquartered in Delaware.
Langue originale de la source: Federal Register — Health and Human ServicesOuvrir le communiqué original →